Overall rank by patents
#20,396
of 50,000 tracked assignees
USPTO PatentsView assignee record - 14 granted patents across 5 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
According to USPTO PatentsView, Shanghai ranks #20,396 of 50,000 tracked US assignees by granted-patent volume, with 14 patents across 5 technology areas.
USPTO PatentsView assignee plate
Corpus R20396 · Foreign Corporation #20,396 · 14 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Seedmaster Manufacturing, Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Shanghai Chuangshi M… · this assignee
38 score
3D Lighting Innovati… · lowest
7 score
What this shows Shanghai's Innovation Score is 38.4/100 (top 41% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Shanghai Chuangshi Medical Technology (group) Co., Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 7.1% of grants classified under A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). Peak complete grant year is 2023 (7 grants) versus a trough of 1 in 2024. By volume, Shanghai sits between Seedmaster Manufacturing, Ltd. and Shantou Chenghai District Lele Brothers Toys Co., Ltd.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SeedMaster Manufacturing, Ltd.
14 patents
Seismos, Inc.
14 patents
Senaya, Inc.
14 patents
Shanghai Awinic Technology Co., Ltd.
14 patents
Shanghai Huali Integrated Circuit Mfg. Co., Ltd.
14 patents
Shanghai Institute of Technical Physics Chinese Academy of Sciences
14 patents
Shanghai Pharmaceuticals Holding Co., Ltd.
14 patents
Shantou Chenghai District Lele Brothers Toys Co., Ltd
14 patents
Shanghai Chuangshi Medical Technology (Group) Co., Ltd.
14 patents
What this shows Shanghai holds 14 patents at rank #20,434, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #20,434 in granted patent volume.
Other assignees with the most granted patents in Shanghai's primary technology class.
Shanghai's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
38 Top 41% higher than 59% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 6 | 42.9% |
| 2023 | 7 | 50.0% |
| 2024 | 1 | 7.1% |
Top 5 of 5 technology areas
Overall rank by patents
#20,396
of 50,000 tracked assignees
38.4 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.